PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33471836-8 2021 The triple combination treatment of mTOR inhibitor AZD2014 and BKM120 or AZD2014 and BYL719 with radiation showed a significantly enhanced inhibitory effect on radioresistant OML1-R cells. NVP-BKM120 63-69 mechanistic target of rapamycin kinase Homo sapiens 36-40 30982255-0 2019 [NVP-BKM120 in combination with letrozole inhibit human breast cancer stem cells via PI3K/mTOR pathway]. NVP-BKM120 5-11 mechanistic target of rapamycin kinase Homo sapiens 90-94 32005746-1 2020 PURPOSE: Concurrent inhibition of mTOR and PI3K led to improved efficacy in preclinical models and provided the rationale for this phase I study of everolimus and buparlisib (BKM120) in patients with advanced solid tumor. NVP-BKM120 163-173 mechanistic target of rapamycin kinase Homo sapiens 34-38 32898555-7 2020 In this study we demonstrate the effects of PI3K/Akt/mTOR pathway inhibition by buparlisib on PD-L1 expression in HNSCC cell lines. NVP-BKM120 80-90 mechanistic target of rapamycin kinase Homo sapiens 53-57 27986714-1 2017 Data from the BELLE-3 trial suggest that adding the investigational PI3K inhibitor buparlisib to endocrine therapy may improve outcomes for patients with hormone receptor-positive advanced breast cancer whose tumors become resistant to mTOR inhibition. NVP-BKM120 83-93 mechanistic target of rapamycin kinase Homo sapiens 236-240 28662162-7 2017 BKM120 exhibited cytotoxicity in MB cells in a dose and time-dependent manner by inhibiting activation of downstream signaling molecules AKT and mTOR, and activating caspase-mediated apoptotic pathways. NVP-BKM120 0-6 mechanistic target of rapamycin kinase Homo sapiens 145-149 27507562-4 2017 The highest inhibitory effect of treatments on cell proliferation, mitogen-activated protein kinase (MAPK) and PI3K/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathways were found with the BKM120-cetuximab association. NVP-BKM120 215-221 mechanistic target of rapamycin kinase Homo sapiens 139-168 27507562-4 2017 The highest inhibitory effect of treatments on cell proliferation, mitogen-activated protein kinase (MAPK) and PI3K/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathways were found with the BKM120-cetuximab association. NVP-BKM120 215-221 mechanistic target of rapamycin kinase Homo sapiens 170-174 26402468-5 2015 Buparlisib inhibited activation of Akt and signaling molecules downstream of mTORC1 (mTOR complex 1) in Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma cell lines. NVP-BKM120 0-10 mechanistic target of rapamycin kinase Homo sapiens 77-81 22159814-7 2012 NVP-BKM120 demonstrated anti-proliferative activity in 11 human gastric cancer cell lines by decreasing mTOR downstream signaling. NVP-BKM120 4-10 mechanistic target of rapamycin kinase Homo sapiens 128-132 27531477-15 2016 The immunohistochemical analysis showed that BKM120 inhibited mTOR activity, and the enhanced WNT/beta-catenin activity reversed the phenotype of inhibitory mTOR induced by BKM120. NVP-BKM120 45-51 mechanistic target of rapamycin kinase Homo sapiens 62-66 27531477-15 2016 The immunohistochemical analysis showed that BKM120 inhibited mTOR activity, and the enhanced WNT/beta-catenin activity reversed the phenotype of inhibitory mTOR induced by BKM120. NVP-BKM120 173-179 mechanistic target of rapamycin kinase Homo sapiens 157-161